• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
APVO

APVO

Aptevo Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS

USD5.02

-0.02 (-0.40%)

Rating:B-

Company Profile

CEO

Jeffrey G. Lamothe

IPO Date

2016-07-20

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.31

Prev. Close

$5.04

Day Low

$5.00

Day High

$5.46

52W Low

$3.80

52W High

$235.98

Market Cap

$0.01B

Volume

0.12M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

42.2%

Avg Negative

1.2%

Avg Neutral

56.4%

News Feed

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Accesswire·8/17/2021·↑ positive

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

Accesswire·8/12/2021·↑ positive

Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference

Accesswire·7/16/2021·↑ positive

Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index

Accesswire
·6/29/2021
·↑ positive

Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?

Zacks Investment Research·6/15/2021·↑ positive

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

Accesswire·4/9/2021·↑ positive

Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update

Accesswire·3/31/2021·↑ positive

An Assessment On Aptevo Therapeutics

Seeking Alpha·3/24/2021·↑ positive

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

Accesswire·1/11/2021·↑ positive

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Seeking Alpha·12/2/2020·↑ positive